We are a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers. Rosiptor (AQX-1125), Aquinox's lead drug candidate, is a small molecule activator of SHIP1, which is a regulating component of the PI3K cellular signaling pathway. By activating SHIP1, rosiptor is believed to decrease the inflammatory process, thereby reducing inflammation and inflammatory pain.

Rosiptor is expected to be suitable for once-daily oral administration with a tolerability profile similar to placebo. Rosiptor has completed enrollment in a Phase 3 trial (LEADERSHIP 301) to treat patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a life-altering, debilitating condition characterized by bladder pain and urinary symptoms that may affect as many as 5.5M adults in the United States alone.1,2,3   

Additionally, a Phase 2 proof-of-concept trial (ProShip 205) evaluating the efficacy and safety of rosiptor in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has been initiated. CP/CPPS is a urological condition characterized by chronic pelvic pain and voiding symptoms present without evidence of urinary tract infection. Estimates suggest up to 5M males in the US have CP/CPPS symptoms, yet there are currently no FDA approved and/or effective treatment options for the condition.4

Preclinical and clinical studies have shown inflammation can be reduced by administration of compounds that activate SHIP1. If the PI3K pathway is overactive, immune cells may produce an abundance of pro-inflammatory signaling molecules, migrating to and concentrating in tissues, resulting in excessive or chronic inflammation.5 Compounds activating SHIP1 may reduce the function and migration of immune cells producing an anti-inflammatory effect. In addition, because SHIP1 is predominantly present in immune cells, off-tissue toxicities may be minimized.

Our longer-term strategy is to leverage our SHIP1 technology to develop drug candidates for the treatment of inflammatory diseases and cancer.



1 Hanno P, Cervigni M, Dinis P, et al. Bladder Pain Syndrome. In: Abrams P, Cardozo L, Wagg A, Wein A, eds. Incontinence. 6th ed. 2017:2206-2275.

2 Berry SH, Elliott MN, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186:540-544.

3 Suskind AM, Berry SH, Ewing BA, et al. The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men; results of the RAND interstitial cystitis epidemiology (RICE) male study. J Urol. 2013;189:141-145.

4 Daniels N, et al. J Natl Med Assoc. 2007; 99(5): 509-516.

5 Patel, RK & Mohan, C. Immunol Res (2005) 31: 47.